Börse:
14,545€
-2,05%
Echtzeit-Aktienkurs Halozyme Therapeutics
Bid:
14,290€
Ask:
14,800€
| Allgemeine Informationen | ||
|---|---|---|
| Börsenwert: | 2,11 Mrd. EUR (144,73 Mio. x 14,545€) | |
| Website: | - | |
| Sektor: | Medizin / Biotechnologie | |
| News-Radar | |
|---|---|
| dpa-AFX Pro - | Newsbot 1 |
| dpa-AFX - | Reuters - |
| 2015 | 2016 | 2017 | 2018 | |
|---|---|---|---|---|
| KUV | 13,80 | 12,84 | 6,56 | 13,86 |
| KGV | - | - | 32,32 | - |
| Div. Rend. | - | - | - | - |
Echtzeit-Chart der Halozyme Therapeutics Aktie
Börsenkurse Halozyme Therapeutics
| Tradegate | 14,434 | 277 | 14,616 | 273 | 14,525 | -2,19% |
| Börse Stuttgart | 14,290€ | 0 | 14,800€ | 0 | 14,545€ | -1,38% |
| Lang & Schwarz | 14,472€ | 5162 | 14,588€ | 5162 | 14,530€ | -2,21% |
| Euro Indikation | 14,290€ | 0 | 14,800€ | 0 | 14,545€ | -2,05% |
| Dollar Indikation | 16,135$ | 0 | 16,499$ | 0 | 16,317$ | -2,82% |
Fundamentaldaten der Halozyme Therapeutics Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2018 | 151,86 Mio. | -123,99 Mio. | -80,33 Mio. | -0,56 | 0,00% | - | 13,86 |
| 2017 | 316,61 Mio. | 61,61 Mio. | 62,97 Mio. | 0,45 | 0,00% | 32,32 | 6,56 |
| 2016 | 146,69 Mio. | -101,86 Mio. | -103,02 Mio. | -0,81 | 0,00% | - | 12,84 |
| 2015 | 135,06 Mio. | -32,23 Mio. | -32,23 Mio. | -0,25 | 0,00% | - | 13,80 |
Profil der Halozyme Therapeutics Aktie
Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
TraderFox GmbH:
Impressum & Datenschutz -
Allgemeine Geschäftsbedingungen